X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-13 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $37.55 | -196,538 | 4,000 | -98% | -$7,379,887 | |||||
2025-11-13 | WVE | Wave Life Sciences Ltd. | Rawcliffe Adrian | Dir | S - Sale | $6.79 | -16,115 | 12,700 | -56% | -$109,421 | ||||||
| D | 2025-11-14 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $30.00 | -3,333 | 84,974 | -4% | -$99,990 | |||||
2025-11-14 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $11.18 | -8,804 | 188,139 | -4% | -$98,401 | ||||||
2025-11-14 | MNKD | Mannkind Corp | Singh Sanjay R | EVP Technical Operations | S - Sale | $5.03 | -18,777 | 455,211 | -4% | -$94,448 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $11.18 | -8,887 | 139,689 | -6% | -$99,329 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $11.18 | -15,485 | 225,454 | -6% | -$173,074 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Doyle Thomas James | SVP, Finance, Accounting | S - Sale | $11.18 | -4,539 | 130,757 | -3% | -$50,732 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $11.18 | -6,902 | 105,373 | -6% | -$77,143 | ||||||
| D | 2025-11-13 | SPRY | Ars Pharmaceuticals, Inc. | Dorsey Brian | COO | S - Sale+OE | $8.71 | -21,828 | 10,789 | -67% | -$190,050 | |||||
| D | 2025-11-12 | SPRY | Ars Pharmaceuticals, Inc. | Chakma Justin | Chief Business Officer | S - Sale+OE | $8.87 | -166,380 | 0 | -100% | -$1,476,147 | |||||
2025-11-13 | WVE | Wave Life Sciences Ltd. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $6.69 | +1,000 | 18,231,824 | 0% | +$6,688 | ||||||
| M | 2025-11-12 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $365.22 | -16,009 | 1,037,226 | -2% | -$5,846,820 | |||||
| D | 2025-11-12 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $349.17 | -996 | 223,106 | 0% | -$347,770 | |||||
| D | 2025-11-12 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $74.50 | -7,333 | 6,666 | -52% | -$546,309 | |||||
| D | 2025-11-12 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale+OE | $11.92 | -131,856 | 146,403 | -47% | -$1,571,724 | |||||
| D | 2025-11-13 | MDGL | Madrigal Pharmaceuticals, Inc. | Levy Richard S | Dir | S - Sale+OE | $520.96 | -8,500 | 21,197 | -29% | -$4,428,198 | |||||
2025-11-12 | CPRX | Catalyst Pharmaceuticals, Inc. | Elsbernd Brian | Chief Compliance, Legal Office | S - Sale | $22.70 | -40,000 | 231,039 | -15% | -$908,000 | ||||||
| D | 2025-11-12 | BBIO | Bridgebio Pharma, Inc. | Valantine Hannah | Dir | S - Sale+OE | $66.07 | -25,484 | 7,863 | -76% | -$1,683,728 | |||||
| D | 2025-11-12 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $40.94 | -19,900 | 31,086 | -39% | -$814,706 | |||||
| M | 2025-11-12 | ANIP | Ani Pharmaceuticals Inc | Gassert Chad | SVP - CORP. DEV., STRATEGY | S - Sale | $89.06 | -14,736 | 232,105 | -6% | -$1,312,435 | |||||
2025-11-13 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $4.74 | -15,000 | 62,252 | -19% | -$71,168 | ||||||
2025-11-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $87.27 | -400 | 75,274 | -1% | -$34,908 | ||||||
| DM | 2025-11-12 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale+OE | $452.75 | -25,650 | 65,816 | -28% | -$11,613,003 | |||||
| D | 2025-11-12 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $194.00 | -30,000 | 36,461 | -45% | -$5,820,061 | |||||
| D | 2025-11-12 | COLL | Collegium Pharmaceutical, Inc | Fallon John A. | Dir | S - Sale+OE | $47.21 | -34,853 | 64,634 | -35% | -$1,645,536 | |||||
| D | 2025-11-12 | AGIO | Agios Pharmaceuticals, Inc. | Scadden David | Dir | S - Sale+OE | $43.84 | -200 | 17,603 | -1% | -$8,768 | |||||
| D | 2025-11-13 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $5.47 | -121,117 | 4,479 | -96% | -$662,510 | |||||
| E | 2025-11-13 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.04 | -46,606 | 93,060,372 | 0% | -$2,062 | |||||
2025-11-12 | CVRX | Cvrx, Inc. | Johnson & Johnson | 10% | S - Sale | $10.00 | -1,000 | 4,049,898 | 0% | -$10,000 | ||||||
2025-11-12 | PRGO | Perrigo Co Plc | Parker Geoffrey M. | Dir | P - Purchase | $14.18 | +7,500 | 72,166 | +12% | +$106,350 | ||||||
2025-11-13 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP, Sales | P - Purchase | $0.10 | +150,000 | 5,784,101 | +3% | +$14,550 | ||||||
2025-11-12 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Dir | P - Purchase | $2.10 | +9,498 | 118,846 | +9% | +$19,946 | ||||||
| AD | 2025-11-11 | TBPH | Theravance Biopharma, Inc. | Broshy Eran | Dir | S - Sale+OE | $17.98 | -45,000 | 60,204 | -43% | -$809,250 | |||||
| D | 2025-11-11 | TBPH | Theravance Biopharma, Inc. | Broshy Eran | Dir | S - Sale+OE | $18.11 | -59,000 | 46,204 | -56% | -$1,068,250 | |||||
| D | 2025-11-11 | VERA | Vera Therapeutics, Inc. | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | S - Sale+OE | $29.06 | -15,000 | 57,839 | -21% | -$435,875 | |||||
| DM | 2025-11-12 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $45.01 | -30,337 | 22,080 | -58% | -$1,365,393 | |||||
| D | 2025-11-11 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $84.70 | -30,000 | 40,555 | -43% | -$2,540,923 | |||||
2025-11-10 | SEPN | Septerna, Inc. | Long Daniel D. | SVP, Drug Discovery | S - Sale | $18.06 | -3,501 | 92,911 | -4% | -$63,223 | ||||||
| D | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale+OE | $44.88 | -119,524 | 19,396 | -86% | -$5,363,716 | |||||
2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $45.44 | -200,000 | 631,305 | -24% | -$9,088,499 | ||||||
| D | 2025-11-13 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $45.99 | -15,000 | 0 | -100% | -$689,797 | |||||
| DM | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Gold Alexander M | Dir | S - Sale+OE | $45.45 | -34,675 | 0 | -100% | -$1,576,095 | |||||
2025-11-11 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $7.40 | -16,667 | 1,336,843 | -1% | -$123,296 | ||||||
| DEM | 2025-11-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $386.63 | -8,000 | 644,489 | -1% | -$3,093,044 | |||||
| D | 2025-11-12 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $21.12 | -100,000 | 23,400 | -81% | -$2,112,450 | |||||
2025-11-11 | EWTX | Edgewise Therapeutics, Inc. | Fox Jonathan C | Dir | P - Purchase | $18.64 | +10,700 | 23,702 | +82% | +$199,403 | ||||||
| M | 2025-11-11 | MRVI | Maravai Lifesciences Holdings, Inc. | Brust Bernd | CEO | P - Purchase | $3.23 | +250,559 | 2,250,559 | +13% | +$809,010 | |||||
| D | 2025-11-12 | CNTA | Centessa Pharmaceuticals Plc | Bush Tia L | Chief Technology, Quality Ofc | S - Sale+OE | $26.00 | -40,000 | 121,503 | -25% | -$1,040,000 | |||||
2025-11-11 | PBYI | Puma Biotechnology, Inc. | Miller Michael Patrick | Dir | S - Sale | $4.86 | -20,000 | 54,000 | -27% | -$97,228 | ||||||
| D | 2025-11-13 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $464.76 | -11,000 | 36,781 | -23% | -$5,112,335 | |||||
| D | 2025-11-11 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $189.68 | -31,226 | 83,111 | -27% | -$5,922,795 | |||||
| D | 2025-11-12 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $11.55 | -3,328 | 398,981 | -1% | -$38,438 | |||||
| E | 2025-11-13 | LLY | Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, CAO | S - Sale | $1.01 | -1,000 | 4,568 | -18% | -$1,011 | |||||
2025-11-10 | PCRX | Pacira Biosciences, Inc. | Cross Shawn | CFO | S - Sale | $22.09 | -12,060 | 56,250 | -18% | -$266,405 | ||||||
| D | 2025-11-11 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $43.78 | -2,454 | 61,727 | -4% | -$107,436 | |||||
2025-11-12 | OGN | Organon & Co. | Cox Carrie Smith | Exec Chair | P - Purchase | $7.67 | +65,400 | 77,869 | +525% | +$501,755 | ||||||
| E | 2025-11-12 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.07 | -305,000 | 93,106,978 | 0% | -$20,231 | |||||
2025-11-12 | CRVO | Cervomed Inc. | Gregoire Sylvie | Dir, 10% | P - Purchase | $7.35 | +5,553 | 1,467,131 | 0% | +$40,815 | ||||||
2025-11-12 | CRVO | Cervomed Inc. | Elder William Robert | CFO, GC, Secretary | P - Purchase | $7.44 | +3,500 | 9,000 | +64% | +$26,040 | ||||||
2025-11-12 | CRVO | Cervomed Inc. | Alam John J | CEO, Pres, 10% | P - Purchase | $7.35 | +5,553 | 1,467,131 | 0% | +$40,815 | ||||||
2025-11-07 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | S - Sale | $2.37 | -40,270 | 869,450 | -4% | -$95,440 | ||||||
2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $16.11 | -412 | 67,159 | -1% | -$6,637 | ||||||
2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | VP, Corporate Controller | S - Sale | $16.10 | -239 | 9,213 | -3% | -$3,848 | ||||||
2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $16.16 | -138 | 15,366 | -1% | -$2,230 | ||||||
2025-11-10 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $16.12 | -95 | 15,750 | -1% | -$1,531 | ||||||
| M | 2025-11-07 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $1.13 | -137,041 | 3,650,433 | -4% | -$154,850 | |||||
| M | 2025-11-07 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $1.13 | -213,529 | 5,691,191 | -4% | -$241,278 | |||||
| M | 2025-11-07 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $1.13 | -213,529 | 5,691,191 | -4% | -$241,278 | |||||
| D | 2025-11-11 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale+OE | $65.08 | -5,175 | 9,977 | -34% | -$336,789 | |||||
2025-11-10 | ASRT | Assertio Holdings, Inc. | Stark David Matthew | Dir | S - Sale | $0.76 | -8,959 | 98,541 | -8% | -$6,806 | ||||||
2025-11-10 | ACAD | Acadia Pharmaceuticals Inc | Daly James M | Dir | S - Sale | $22.37 | -30,000 | 4,041 | -88% | -$670,983 | ||||||
| M | 2025-11-10 | TRDA | Entrada Therapeutics, Inc. | Baker Bros. Advisors LP | 10% | P - Purchase | $7.60 | +178,044 | 4,664,924 | +4% | +$1,352,587 | |||||
2025-11-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $17.40 | -6,667 | 269,974 | -2% | -$116,034 | ||||||
| D | 2025-11-10 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $452.08 | -22,500 | 2,648 | -89% | -$10,171,683 | |||||
| D | 2025-11-10 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $452.07 | -21,000 | 8,118 | -72% | -$9,493,483 | |||||
| D | 2025-11-07 | LGND | Ligand Pharmaceuticals Inc | Gray Nancy Ryan | Dir | S - Sale+OE | $205.45 | -6,571 | 8,094 | -45% | -$1,350,012 | |||||
| D | 2025-11-07 | LGND | Ligand Pharmaceuticals Inc | Lamattina John L | Dir | S - Sale+OE | $205.45 | -4,179 | 30,724 | -12% | -$858,576 | |||||
2025-11-11 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $5.25 | -40,000 | 5,832,207 | -1% | -$210,000 | ||||||
2025-11-10 | APVO | Aptevo Therapeutics Inc. | Grant Grady III | Dir | P - Purchase | $1.49 | +13,513 | 13,514 | >999% | +$20,134 | ||||||
| DM | 2025-11-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $450.10 | -8,000 | 644,489 | -1% | -$3,600,830 | |||||
2025-11-07 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale | $25.09 | -29,004 | 155,334 | -16% | -$727,674 | ||||||
| DM | 2025-11-07 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $99.00 | -22,866 | 20,814 | -52% | -$2,263,826 | |||||
| D | 2025-11-07 | EVMN | Evommune, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $16.00 | +1,250,000 | 784,345 | -268% | +$20,000,000 | |||||
| D | 2025-11-07 | EVMN | Evommune, Inc. | Lsp 7 Cooperative Ua | 10% | P - Purchase | $16.00 | +1,562,500 | 4,929,633 | +46% | +$25,000,000 | |||||
| D | 2025-11-07 | EVMN | Evommune, Inc. | Verduyn-Van Weegen Felice Isabel | Dir, 10% | P - Purchase | $16.00 | +1,562,500 | 4,929,633 | +46% | +$25,000,000 | |||||
2025-11-10 | EBS | Emergent Biosolutions Inc. | Degolyer Donald W | Dir | S - Sale | $10.54 | -17,801 | 119,858 | -13% | -$187,623 | ||||||
| D | 2025-11-07 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale+OE | $18.97 | -50,291 | 214,232 | -19% | -$954,066 | |||||
| D | 2025-11-10 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $6.03 | -1,867 | 834,592 | 0% | -$11,252 | |||||
2025-11-10 | MRK | Merck & Co., Inc. | Downing Cristal N | Chief Comm., Public Afrs Ofcr | S - Sale | $87.00 | -7,085 | 0 | -100% | -$616,395 | ||||||
| D | 2025-11-10 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $6.03 | -5,291 | 7,614 | -41% | -$31,884 | |||||
| E | 2025-11-11 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $974.70 | -283,131 | 93,411,978 | 0% | -$275,967,765 | |||||
2025-11-10 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $972.52 | -16,869 | 93,695,109 | 0% | -$16,405,396 | ||||||
| D | 2025-11-10 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $4.10 | -6,500 | 0 | -100% | -$26,650 | |||||
2025-10-28 | ANVS | Annovis Bio, Inc. | Maccecchini Maria-Luisa | Pres, CEO | P - Purchase | $2.05 | +97,561 | 1,212,020 | +9% | +$200,000 | ||||||
2025-10-28 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $2.05 | +975,610 | 2,678,896 | +57% | +$2,000,001 | ||||||
2025-11-10 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP, Sales | P - Purchase | $0.10 | +120,000 | 5,634,101 | +2% | +$11,760 | ||||||
2025-11-07 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.43 | +10,600 | 5,583,502 | 0% | +$89,358 | ||||||
2025-11-07 | BNTC | Benitec Biopharma Inc. | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $13.50 | +1,481,481 | 1,819,812 | +438% | +$19,999,994 | ||||||
| M | 2025-11-07 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $45.09 | -41,823 | 37,417 | -53% | -$1,885,618 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |